Differences in the renal antifibrotic cGMP/cGKI-dependent signaling of serelaxin, zaprinast, and their combination
Sign Up to like & getrecommendations! Published in 2017 at "Naunyn-Schmiedeberg's Archives of Pharmacology"
DOI: 10.1007/s00210-017-1394-z
Abstract: Renal fibrosis is an important factor for end-stage renal failure. However, only few therapeutic options for its treatment are established. Zaprinast, a phosphodiesterase 5 inhibitor, and serelaxin, the recombinant form of the naturally occurring hormone… read more here.
Keywords: combination; fibrosis; serelaxin; zaprinast ... See more keywords